

Hepsin-QF, CACTCAGCCCCGAGACCA (SEQ ID NO: 3);  
Hepsin-QR, AGTCCCAGACAGCAGAACATATT (SEQ ID NO: 4); and  
Hepsin-QP, [6-FAM]-CCAACCTCACCCCTCCTGACCCCC (SEQ ID NO: 5)-  
[TAMRA].

*a3  
out*

**Page 67, line 29, paragraph 6:** Please amend as follows:

*AM*  
Polyclonal hepsin antibodies were generated using a 19-mer C-terminal peptide (WIFQAIKTHSEASGMVTQL) (SEQ ID NO: 6) and affinity purified by Antibody Solutions (Palo Alto, CA). Commercial anti-rabbit IgG (control) was purchased from Pierce and washed with phosphate


**Page 74, at the end of the specification, please insert the printed Sequence Listing submitted concurrently herewith.**

**REMARKS**

Applicants submit this Amendment to insert the required SEQ ID NOS of the Sequence Listing filed concurrently herewith and to indicate the insertion point for the Sequence Listing.

Applicants respectfully request examination on the merits of this application.

Respectfully submitted,



John P. Isacson  
Reg. No. 33,715

June 17, 2002

Date

HELLER EHRMAN WHITE & MCAULIFFE LLP  
1666 K Street, N.W., Suite 300  
Washington, DC 20006  
Telephone: (202) 912-2000  
Facsimile: (202) 912-2020



26633